Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
-- Presented additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial of bempikibart in late-breaking oral and poster presentations at EADV Congress 2026; data supports further development of bempikibart as a chronic treatment in AA -- -- Robust...